Research and Development
Patent name | Patent number | Registered jurisdiction area | Date of application | Due date |
A novel recombinant bifunctional fusion protein and its preparation and use | 201110178342.9 | PCT、CN | 2011/6/28 | 2031/6/28 |
New recombinant bifunctional fusion protein, preparation method therefor and use thereof | 201410136962.X | PCT、CN | 2014/4/4 | 2034/4/4 |
Novel recombinant fusion protein, preparation method therefor and use thereof | 201310283328.4 | PCT、CN | 2013/7/5 | 2033/7/5 |
Recombinant human vascular endothelial growth factor receptor-antibody fusion protein pharmaceutical combination preparation | 201810433564.2 | PCT、CN | 2018/5/8 | 2038/5/8 |
Antibody targeting interleukin 17a and preparation method and application thereof | 201710602383.3 | PCT、CN、US、JP、EP、HK | 2017/7/21 | 2037/7/21 |
Anti-interleukin-17a antibody, preparation method therefor, and application thereof | 201710916535.7 | PCT、CN、HK | 2017/9/30 | 2037/9/30 |
Humanized anti-human IL-17 A monoclonal antibody pharmaceutical composition | 201910935046.5 | CN | 2019/9/29 | 2039/9/29 |
Lag-3 antibody having high affinity and high biological activity, and application thereof | 201810614764.8 | PCT、CN | 2018/6/14 | 2038/6/14 |
Binder against programmed death-ligand and application thereof | 201910258182.5 | PCT、CN、US、JP、EP、HK | 2019/4/1 | 2039/4/1 |
Anti-pd-l1/vegf bifunctional antibody and use thereof | 201910258153.9 | PCT、CN、US、JP、EP、HK、AU、KR | 2019/4/1 | 2039/4/1 |
Anti-TIGIT antibodies, preparation method and use thereof | 202010387630.4 | PCT、CN、US、JP、EP、HK、AU、KR、TW | 2020/5/9 | 2040/5/9 |
Antibody targeting interleukin 36R and preparation method and application thereof | 202011213729.9 | PCT、CN、US、JP、EP、HK、AU、KR、TW | 2020/11/4 | 2040/11/4 |